NRIX Nurix Therapeutics Inc

USD 14.70 0.16 1.100413
Icon

Nurix Therapeutics Inc (NRIX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 14.70

+0.16 (+1.10)%

USD 0.66B

1.31M

USD 25.80(+75.51%)

USD 33.00 (+124.49%)

Icon

NRIX

Nurix Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 14.70
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.66B

USD 33.00 (+124.49%)

USD 14.70

Nurix Therapeutics Inc (NRIX) Stock Forecast

Show ratings and price targets of :
USD 25.80
(+75.51%)

Based on the Nurix Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Nurix Therapeutics Inc is USD 25.80 over the next 12 months. Nurix Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Nurix Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Nurix Therapeutics Inc’s stock price was USD 14.70. Nurix Therapeutics Inc’s stock price has changed by +12.90% over the past week, +23.43% over the past month and +68.97% over the last year.

No recent analyst target price found for Nurix Therapeutics Inc
No recent average analyst rating found for Nurix Therapeutics Inc

Company Overview Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orall...Read More

https://www.nurixtx.com

1700 Owens Street, San Francisco, CA, United States, 94158

284

November

USD

USA

Adjusted Closing Price for Nurix Therapeutics Inc (NRIX)

Loading...

Unadjusted Closing Price for Nurix Therapeutics Inc (NRIX)

Loading...

Share Trading Volume for Nurix Therapeutics Inc Shares

Loading...

Compare Performance of Nurix Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for NRIX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Nurix Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing NRIX

Symbol Name NRIX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Nurix Therapeutics Inc (NRIX) Stock

Based on ratings from 4 analysts Nurix Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.

Unfortunately we do not have enough data on NRIX's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for NRIX is USD 25.80 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 20.

Unfortunately we do not have enough data on NRIX's stock to indicate if its overvalued.

The last closing price of NRIX's stock was USD 14.70.

The most recent market capitalization for NRIX is USD 0.66B.

Based on targets from 4 analysts, the average taret price for NRIX is projected at USD 25.80 over the next 12 months. This means that NRIX's stock price may go up by +75.51% over the next 12 months.

We can't find any ETFs which contains Nurix Therapeutics Inc's stock.

As per our most recent records Nurix Therapeutics Inc has 284 Employees.

Nurix Therapeutics Inc's registered address is 1700 Owens Street, San Francisco, CA, United States, 94158. You can get more information about it from Nurix Therapeutics Inc's website at https://www.nurixtx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...